Kiselak Tomas — SEC Form 4 filings
SEC reporting owner CIK 1830177. 41 Form 4 filings on record with FilingPulse; latest filed 2026-09-10.
Transaction summary — filings shown
Covers all 41 filings on record, filed 2024-01-24 to 2026-09-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 6 legs across 6 filings — 3,279,669 shares, $49,820,786 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 3 filings — 9,988,191 shares, $833,198,073 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 84.
- Largest priced transaction: sale of 4,684,781 shares @ $85.31 ($399,658,667) in Spyre Therapeutics, Inc., filed 2026-06-23.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | Director | 5 | — | 1 leg · 4,684,781 sh · $399,658,667 | 9 |
| Oruka Therapeutics, Inc. (ORKA) | Director, 10% owner | 6 | — | 1 leg · 3,553,410 sh · $300,014,406 | 9 |
| Apogee Therapeutics, Inc. (APGE) | Director | 8 | — | 1 leg · 1,750,000 sh · $133,525,000 | 24 |
| CRESCENT BIOPHARMA, INC. (CBIO) | Director, 10% owner | 4 | 2 legs · 2,213,450 sh · $30,612,625 | — | 4 |
| Zenas BioPharma, Inc. (ZBIO) | Director | 5 | 4 legs · 1,066,219 sh · $19,208,161 | — | 19 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | Director | 4 | — | — | 6 |
| Damora Therapeutics, Inc. (DMRA) | 10% owner | 2 | — | — | 5 |
| Jade Biosciences, Inc. (JBIO) | Director, 10% owner | 3 | — | — | 4 |
| Viridian Therapeutics, Inc.\DE (VRDN) | Director | 3 | — | — | 3 |
| Korsana Biosciences, Inc. (KRSA) | Director, 10% owner | 1 | — | — | 1 |
Form 4 filings — Kiselak Tomas
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-10 | 4 | Korsana Biosciences, Inc. (KRSA) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest VI L.P., Harwin Peter Evan | Grant/award (A): 48,445 (derivative) @ $0 | EDGAR |
| 2026-09-03 | 4 | Apogee Therapeutics, Inc. (APGE) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Harwin Peter Evan | Disposition to issuer (D): 340,855 · Disposition to issuer (D): 51,166 · Disposition to issuer (D): 51,166 · Disposition to issuer (D): 6,743,321 (derivative) · Disposition to issuer (D): 47,758 (derivative) · Disposition to issuer (D): 10,370 (derivative) · +2 more | EDGAR |
| 2026-08-11 | 4 | Apogee Therapeutics, Inc. (APGE) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Harwin Peter Evan | Option exercise (M): 31,838 @ $17 · Option exercise (M): 10,370 @ $43.85 · Option exercise (M): 31,838 (derivative) @ $0 · Option exercise (M): 10,370 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | CRESCENT BIOPHARMA, INC. (CBIO) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Harwin Peter Evan | Purchase (P): 853,450 @ $14.50 · Purchase (P): 525,897 (derivative) @ $14.50 | EDGAR |
| 2026-07-02 | 4 | Viridian Therapeutics, Inc.\DE (VRDN) | Grant/award (A): 32,341 (derivative) @ $0 | EDGAR |
| 2026-07-01 | 4 | Oruka Therapeutics, Inc. (ORKA) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest III L.P., Harwin Peter Evan | Conversion (C): 3,553,410 · Sale (S): 3,553,410 @ $84.43 · Conversion (C): 42,641 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Spyre Therapeutics, Inc. (SYRE) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Harwin Peter Evan | Conversion (C): 666,680 · Sale (S): 4,684,781 @ $85.31 · Conversion (C): 16,667 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Jade Biosciences, Inc. (JBIO) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest IV L.P., Harwin Peter Evan | Grant/award (A): 34,843 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Apogee Therapeutics, Inc. (APGE) jointly with Fairmount Funds Management LLC | Grant/award (A): 7,657 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | CRESCENT BIOPHARMA, INC. (CBIO) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Harwin Peter Evan | Grant/award (A): 11,050 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Oruka Therapeutics, Inc. (ORKA) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest III L.P., Harwin Peter Evan | Grant/award (A): 9,136 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Spyre Therapeutics, Inc. (SYRE) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P. | Grant/award (A): 8,026 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Zenas BioPharma, Inc. (ZBIO) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Harwin Peter Evan | Purchase (P): 150,000 @ $20 | EDGAR |
| 2026-03-25 | 4 | Damora Therapeutics, Inc. (DMRA) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest V L.P., Harwin Peter Evan | Grant/award (A): 37,313 (derivative) @ $0 | EDGAR |
| 2026-02-12 | 4 | Galecto, Inc. (GLTO) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest V L.P., Harwin Peter Evan | Option exercise (M): 5,809,000 @ $0 · Option exercise (M): 2,904,000 @ $0 · Option exercise (M): 5,809 (derivative) @ $0 · Option exercise (M): 2,904 (derivative) @ $0 | EDGAR |
| 2026-01-22 | 4 | Apogee Therapeutics, Inc. (APGE) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Harwin Peter Evan | Sale (S): 1,750,000 @ $76.30 | EDGAR |
| 2025-12-08 | 4 | CRESCENT BIOPHARMA, INC. (CBIO) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Harwin Peter Evan | Purchase (P): 1,360,000 @ $13.41 · Purchase (P): 131,434 (derivative) @ $13.41 | EDGAR |
| 2025-10-09 | 4 | Zenas BioPharma, Inc. (ZBIO) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Harwin Peter Evan | Purchase (P): 316,219 @ $19 | EDGAR |
| 2025-10-08 | 4 | Jade Biosciences, Inc. (JBIO) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest IV L.P., Harwin Peter Evan | Grant/award (A): 1,333,126 @ $9.14 · Grant/award (A): 855,047 (derivative) @ $9.14 | EDGAR |
| 2025-09-19 | 4 | Oruka Therapeutics, Inc. (ORKA) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest III L.P., Harwin Peter Evan | Grant/award (A): 333,340 @ $15 | EDGAR |
| 2025-07-02 | 4 | Viridian Therapeutics, Inc.\DE (VRDN) | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | GLYCOMIMETICS INC (CBIO) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Harwin Peter Evan | Grant/award (A): 9,023 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Apogee Therapeutics, Inc. (APGE) jointly with Fairmount Funds Management LLC, Harwin Peter Evan | Grant/award (A): 14,461 (derivative) @ $0 · Grant/award (A): 14,461 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Zenas BioPharma, Inc. (ZBIO) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Harwin Peter Evan | Grant/award (A): 18,500 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Oruka Therapeutics, Inc. (ORKA) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest III L.P., Harwin Peter Evan | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Spyre Therapeutics, Inc. (SYRE) jointly with Fairmount Funds Management LLC, Harwin Peter Evan, Fairmount Healthcare Fund II L.P. | Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-05-01 | 4 | Jade Biosciences, Inc. (JBIO) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Harwin Peter Evan | Grant/award (A): 23,017 (derivative) @ $0 | EDGAR |
| 2024-11-21 | 4 | Oruka Therapeutics, Inc. (ORKA) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Harwin Peter Evan | Option exercise (M): 160,000 · Option exercise (M): 160 (derivative) @ $0 | EDGAR |
| 2024-10-01 | 4 | Dianthus Therapeutics, Inc. /DE/ (DNTH) jointly with Fairmount Funds Management LLC | Other (J): 62,146 @ $0 | EDGAR |
| 2024-09-17 | 4/A | Zenas BioPharma, Inc. (ZBIO) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Harwin Peter Evan | Conversion (C): 41,130 · Conversion (C): 252,890 · Conversion (C): 709,794 · Conversion (C): 301,077 · Purchase (P): 300,000 @ $17 · Conversion (C): 357,143 (derivative) · +4 more | EDGAR |
| 2024-09-16 | 4 | Zenas BioPharma, Inc. (ZBIO) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Harwin Peter Evan | Conversion (C): 41,130 · Conversion (C): 252,890 · Conversion (C): 709,794 · Conversion (C): 301,077 · Purchase (P): 300,000 @ $17 · Conversion (C): 357,143 (derivative) · +4 more | EDGAR |
| 2024-09-13 | 4 | Oruka Therapeutics, Inc. (ORKA) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Harwin Peter Evan | Grant/award (A): 275,000 @ $23 · Grant/award (A): 160 (derivative) @ $23,000 | EDGAR |
| 2024-06-28 | 4 | Viridian Therapeutics, Inc.\DE (VRDN) | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Apogee Therapeutics, Inc. (APGE) jointly with Fairmount Funds Management LLC, Harwin Peter Evan | Grant/award (A): 10,370 (derivative) @ $0 · Grant/award (A): 10,370 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | Dianthus Therapeutics, Inc. /DE/ (DNTH) jointly with Fairmount Funds Management LLC | Grant/award (A): 11,000 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | Spyre Therapeutics, Inc. (SYRE) jointly with Fairmount Funds Management LLC, Harwin Peter Evan | Grant/award (A): 11,323 (derivative) @ $0 · Grant/award (A): 11,323 (derivative) @ $0 | EDGAR |
| 2024-04-25 | 4 | Spyre Therapeutics, Inc. (SYRE) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Harwin Peter Evan | Option exercise (M): 3,639,680 @ $0 · Option exercise (M): 90,992 (derivative) @ $0 | EDGAR |
| 2024-04-01 | 4 | Apogee Therapeutics, Inc. (APGE) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund L.P., Fairmount Healthcare Fund II L.P., Harwin Peter Evan | Other (J): 55,913 · Other (J): 55,913 · Other (J): 221,426 (derivative) @ $0 · Other (J): 221,426 (derivative) @ $0 | EDGAR |
| 2024-04-01 | 4 | Dianthus Therapeutics, Inc. /DE/ (DNTH) jointly with Fairmount Funds Management LLC | Other (J): 58,857 · Other (J): 58,857 | EDGAR |
| 2024-01-31 | 4 | Apogee Therapeutics, Inc. (APGE) jointly with Fairmount Funds Management LLC, Fairmount Healthcare Fund L.P., Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest II L.P., Harwin Peter Evan | Other (J): 892,529 @ $0 · Other (J): 51,166 @ $0 · Other (J): 51,166 @ $0 | EDGAR |
| 2024-01-24 | 4 | Dianthus Therapeutics, Inc. /DE/ (DNTH) jointly with Fairmount Funds Management LLC, Harwin Peter Evan | Grant/award (A): 834,334 @ $12 · Grant/award (A): 832,333 (derivative) @ $12.00 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1830177 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →